Forbion Capital Partners

Forbion is a global venture capital firm with deep expertise in Europe, managing approximately €5 billion across multiple fund strategies that cover all stages of (bio-)pharmaceutical drug development. The firm invests in innovative biotech companies and sustainable solutions that improve human and planetary health. Forbion's team consists of over 30 investment professionals who have built an impressive performance track record since the late nineties with 128 investments across 11 funds.

The firm's investment strategy focuses on sectors such as biotechnology, pharmaceuticals, medical devices, and sustainable technologies, including agriculture, food, materials, and environmental technologies. Forbion's funds include Forbion Ventures VII, Forbion Growth Opportunities Fund III, and Forbion BioEconomy Fund I, with sizes of €890 million, €1.2 billion, and €200 million respectively. The firm has offices in Naarden, The Netherlands; Munich, Germany; and Boston, USA.

Forbion's portfolio includes companies like Azafaros, VectorY, and Genomines, which are developing innovative therapeutics and sustainable solutions. The firm has a strong track record of sourcing, building, and guiding life sciences companies, resulting in numerous breakthrough therapies and successful exits. Forbion is a signatory to the United Nations Principles for Responsible Investment, reflecting its commitment to investments that positively impact the health and well-being of people and the planet.